BACKGROUND: Frameless stereotactic radiosurgery is commonly used to treat intracranial metastases, but mask-based immobilization can be uncomfortable for patients. OBJECTIVE: To describe the clinical outcomes using a novel real-time, frameless, surface imaging--guided radiosurgery (SIG-RS) technique to treat brain metastases. METHODS: Data were prospectively gathered for 44 consecutive patients totaling 115 intracranial metastases treated with SIG-RS in a median of 1 fraction (range, 1-5) to a median dose of 20 Gy (range, 15-30 Gy). Local control, regional control, and overall survival were estimated by the Kaplan-Meier method. RESULTS: Median follow-up for all patients was 6.0 months (range, 0.3-21.6 months), with 31 of 44 (70%) deceased at the time of analysis. The 35 patients (80%) with follow-up imaging totaled 88 lesions evaluable for local control. Actuarial 6- and 12-month local control was 90% (95% confidence interval, 82-98) and 76% (95% confidence interval, 60-91), respectively. Regional failure was observed in 16 patients (46%). The median actuarial overall survival was 7.7 months (95% confidence interval, 5.7-9.7). Analysis of the subset of 22 patients (55 lesions) who received SIG-RS alone (no prior treatment) in a single fraction yielded comparable clinical outcomes. Grade 3 or greater toxicity occurred in 4 patients (9%). The median treatment time from beam on to beam off was 15 minutes (range, 3-36 minutes). CONCLUSION: SIG-RS for treating intracranial metastases can produce clinical outcomes comparable to those with conventional frame-based and frameless stereotactic radiosurgery techniques while providing greater patient comfort with an open-faced mask and fast treatment times.
BACKGROUND: Frameless stereotactic radiosurgery is commonly used to treat intracranial metastases, but mask-based immobilization can be uncomfortable for patients. OBJECTIVE: To describe the clinical outcomes using a novel real-time, frameless, surface imaging--guided radiosurgery (SIG-RS) technique to treat brain metastases. METHODS: Data were prospectively gathered for 44 consecutive patients totaling 115 intracranial metastases treated with SIG-RS in a median of 1 fraction (range, 1-5) to a median dose of 20 Gy (range, 15-30 Gy). Local control, regional control, and overall survival were estimated by the Kaplan-Meier method. RESULTS: Median follow-up for all patients was 6.0 months (range, 0.3-21.6 months), with 31 of 44 (70%) deceased at the time of analysis. The 35 patients (80%) with follow-up imaging totaled 88 lesions evaluable for local control. Actuarial 6- and 12-month local control was 90% (95% confidence interval, 82-98) and 76% (95% confidence interval, 60-91), respectively. Regional failure was observed in 16 patients (46%). The median actuarial overall survival was 7.7 months (95% confidence interval, 5.7-9.7). Analysis of the subset of 22 patients (55 lesions) who received SIG-RS alone (no prior treatment) in a single fraction yielded comparable clinical outcomes. Grade 3 or greater toxicity occurred in 4 patients (9%). The median treatment time from beam on to beam off was 15 minutes (range, 3-36 minutes). CONCLUSION:SIG-RS for treating intracranial metastases can produce clinical outcomes comparable to those with conventional frame-based and frameless stereotactic radiosurgery techniques while providing greater patient comfort with an open-faced mask and fast treatment times.
Authors: Q Zhang; D Zheng; Y Lei; B Morgan; J Driewer; M Zhang; S Li; S Zhou; W Zhen; R Thompson; A Wahl; C Lin; C Enke Journal: Br J Radiol Date: 2014-09-16 Impact factor: 3.039
Authors: Steven K M Lau; Xiao Zhao; Ruben Carmona; Erik Knipprath; Daniel R Simpson; Sameer K Nath; Gwe-Ya Kim; Jona A Hattangadi; Clark C Chen; Kevin T Murphy Journal: Transl Cancer Res Date: 2014-08-01 Impact factor: 1.241
Authors: Steven K M Lau; Kaveh Zakeri; Xiao Zhao; Ruben Carmona; Erik Knipprath; Daniel R Simpson; Sameer K Nath; Gwe-Ya Kim; Parag Sanghvi; Jona A Hattangadi-Gluth; Clark C Chen; Kevin T Murphy Journal: Neurosurgery Date: 2015-08 Impact factor: 4.654
Authors: Brian R Hirshman; Bayard Wilson; Mir Amaan Ali; James A Proudfoot; Takao Koiso; Osamu Nagano; Bob S Carter; Toru Serizawa; Masaaki Yamamoto; Clark C Chen Journal: Neurosurgery Date: 2018-04-01 Impact factor: 4.654
Authors: Steven K M Lau; Kunal Patel; Teddy Kim; Erik Knipprath; Gwe-Ya Kim; Laura I Cerviño; Joshua D Lawson; Kevin T Murphy; Parag Sanghvi; Bob S Carter; Clark C Chen Journal: J Neurooncol Date: 2017-01-24 Impact factor: 4.130
Authors: Deborah C Marshall; Logan P Marcus; Teddy E Kim; Brandon A McCutcheon; Steven J Goetsch; Takao Koiso; John F Alksne; Kenneth Ott; Bob S Carter; Jona A Hattangadi-Gluth; Masaaki Yamamoto; Clark C Chen Journal: J Neurooncol Date: 2016-03-07 Impact factor: 4.130
Authors: Sang Kyu Lee; Sheng Huang; Lei Zhang; Ase M Ballangrud; Michalis Aristophanous; Laura I Cervino Arriba; Guang Li Journal: J Appl Clin Med Phys Date: 2021-03-31 Impact factor: 2.102